百济神州(06160.HK)治疗淋巴瘤药品临床数据更新
百济神州(06160.HK)公布,公司日前公布其抗PD-1抗体替雷利珠单抗在中国开展的三项临床试验结果,共有七项替雷利珠单抗数据的口头报告在第22届中国临床肿瘤学会年会上被公布,其中五项是有关全新或更新的数据。
此外,另有替雷利珠单抗、泽布替尼、pamiparib的临床数据在四项海报中被展示。其中,雷利珠单抗在内地获批用於治疗经典型霍奇金淋巴瘤和尿路上皮癌。截至数据截点2019年2月25日,54位患者接受了替雷利珠单抗治疗,中位治疗时间为38.4周(3-79)。14位患者截至数据截点仍在接受治疗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.